Skip to content
value.today

IRulya Therapeutics Inc.: peers

Change the peers

IRulya Therapeutics Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

PureTech Health plc: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

IRulya Therapeutics Inc., Cabaletta Bio, Inc., Atea Pharmaceuticals, Inc., Kyverna Therapeutics, Inc., PureTech Health plc, EyePoint Pharmaceuticals, Inc., Zura Bio Ltd, Relmada Therapeutics, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureIRulya Therapeutics Inc.base
IRLA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Cabaletta Bio, Inc.
CABA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Atea Pharmaceuticals, Inc.
AVIR · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Kyverna Therapeutics, Inc.
KYTX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
PureTech Health plc
PRTC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
EyePoint Pharmaceuticals, Inc.
EYPT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Zura Bio Ltd
ZURA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Relmada Therapeutics, Inc.
RLMD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$343 MOct 30, 2026 · Market data5th of 8$343 MOct 30, 2026 · Market data3rd of 8$343 MOct 29, 2026 · Market data4th of 8$341 MOct 26, 2026 · Market data6th of 8$350 MAug 1, 2026 · Market data1st of 8$349 MOct 14, 2026 · Market data2nd of 8$340 MOct 23, 2026 · Market data7th of 8$337 MOct 20, 2026 · Market data8th of 8$343 M8 ranked
Revenue (Better neither way: ranked highest first)————————$5 MFY2025 · ESEF2nd of 2$31 MFY2025 · SEC1st of 2————$18 M2 ranked
Net income (Higher is better)$-84 MFY2025 · SEC3rd of 8$-168 MFY2025 · SEC7th of 8$-158 MFY2025 · SEC5th of 8$-161 MFY2025 · SEC6th of 8$-110 MFY2025 · ESEF4th of 8$-232 MFY2025 · SEC8th of 8$-69 MFY2025 · SEC2nd of 8$-57 MFY2025 · SEC1st of 8$-134 M8 ranked
Employees (Better neither way: ranked highest first)55As on 2021 · Profile4th of 7156December 31, 2025 · Profile1st of 719As on September 2020 · Profile6th of 7130March 1, 2026 · Profile2nd of 7——123As on 2021 · Profile3rd of 740December 31, 2025 · Profile5th of 710As on 2021 · Profile7th of 7557 ranked
Growth
Revenue growth (Higher is better)————————————————-3.5%FY2025 · ESEF1st of 219th20th-27.5%FY2025 · SEC2nd of 29th4th————————-15.5%2 ranked
Revenue growth, 3 years a year (Higher is better)————————————————————-8.8%FY2025 · SEConly one with it13th11th————————-8.8%—
Margins and returns
Operating margin (Higher is better)————————————————————-776.0%FY2025 · SEConly one with it2nd1st————————-776.0%—
Net margin (Higher is better)————————————————————-739.4%FY2025 · SEConly one with it2nd1st————————-739.4%—
Free cash flow margin (Higher is better)————————————————————-775.9%FY2025 · SEConly one with it2nd1st————————-775.9%—
Return on equity (Higher is better)————-127.0%FY2025 · SEC7th of 719th8th-44.3%FY2025 · SEC2nd of 746th20th-64.7%FY2025 · SEC4th of 736th15th-30.8%FY2025 · ESEF1st of 753rd23rd-72.2%FY2025 · SEC5th of 733rd14th-55.3%FY2025 · SEC3rd of 741st17th-94.1%FY2025 · SEC6th of 726th11th-64.7%7 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————————————————75.1×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price11.1×price Oct 14, 2026 · Market dataonly one with it75th90th————————11.1×—
Price to book (Better neither way: ranked highest first)————3.1×price Oct 30, 2026 · Market data3rd of 650th63rd1.2×price Oct 29, 2026 · Market data5th of 624th28th1.5×price Oct 26, 2026 · Market data4th of 629th35th1.1×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price1.1×price Oct 14, 2026 · Market data6th of 621st25th3.4×price Oct 23, 2026 · Market data2nd of 654th65th3.9×price Oct 20, 2026 · Market data1st of 659th70th2.3×6 ranked
Free cash flow yield (Higher is better)-12.2%price Oct 30, 2026 · Market data1st of 740th19th-38.6%price Oct 30, 2026 · Market data4th of 722nd9th-35.9%price Oct 29, 2026 · Market data3rd of 723rd10th-45.1%price Oct 26, 2026 · Market data5th of 720th8th-24.3%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-69.7%price Oct 14, 2026 · Market data7th of 713th5th-19.1%price Oct 23, 2026 · Market data2nd of 733rd15th-62.2%price Oct 20, 2026 · Market data6th of 715th6th-38.6%7 ranked
Financial strength
Debt to equity (Lower is better)————————————0.1×FY2025 · SEConly one with it21st15th————————————————0.1×—
Interest cover (Higher is better)————-86.1×FY2025 · SEConly one with it16th7th————————————————————————-86.1×—
Scorecard
Scorecard (Higher is better)1 of 12FY2025 · Scorecard6th of 81 of 12FY2025 · Scorecard6th of 84 of 13FY2025 · Scorecard2nd of 84 of 12FY2025 · Scorecard1st of 80 of 5FY2025 · Scorecard8th of 82 of 20FY2025 · Scorecard4th of 81 of 10FY2025 · Scorecard4th of 82 of 12FY2025 · Scorecard3rd of 810% passed8 ranked
Valuation checks (Higher is better)0 of 4FY2025 · Scorecard4th of 70 of 4FY2025 · Scorecard4th of 71 of 4FY2025 · Scorecard1st of 71 of 4FY2025 · Scorecard1st of 7——1 of 5FY2025 · Scorecard3rd of 70 of 4FY2025 · Scorecard4th of 70 of 4FY2025 · Scorecard4th of 70% passed7 ranked
Growth checks (Higher is better)0 of 2FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard2nd of 80 of 1FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard2nd of 80 of 6FY2025 · Scorecard2nd of 80 of 1FY2025 · Scorecard2nd of 81 of 2FY2025 · Scorecard1st of 80% passed8 ranked
Profitability checks (Higher is better)0 of 2FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard1st of 80 of 2FY2025 · Scorecard1st of 80 of 2FY2025 · Scorecard1st of 80 of 5FY2025 · Scorecard1st of 80 of 2FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard1st of 80% passed8 ranked
Financial health checks (Higher is better)1 of 3FY2025 · Scorecard5th of 81 of 3FY2025 · Scorecard5th of 81 of 2FY2025 · Scorecard2nd of 83 of 4FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard8th of 81 of 3FY2025 · Scorecard5th of 81 of 2FY2025 · Scorecard2nd of 81 of 2FY2025 · Scorecard2nd of 842% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard2nd of 6——2 of 2FY2025 · Scorecard1st of 60 of 1FY2025 · Scorecard2nd of 6——0 of 1FY2025 · Scorecard2nd of 60 of 1FY2025 · Scorecard2nd of 60 of 1FY2025 · Scorecard2nd of 60% passed6 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)20.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 787.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 773.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 755.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7——84.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 772.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 797.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 773.5%7 ranked
Institutions holding (Better neither way: ranked highest first)332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 71632026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 71272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 71282026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7——1902026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 71222026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 71352026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 71287 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——+17.5 pp2026-Q2 against 2026-Q1 · 13F1st of 6-1.3 pp2026-Q2 against 2026-Q1 · 13F6th of 6+3.2 pp2026-Q2 against 2026-Q1 · 13F4th of 6——+1.0 pp2026-Q2 against 2026-Q1 · 13F5th of 6+6.0 pp2026-Q2 against 2026-Q1 · 13F3rd of 6+13.6 pp2026-Q2 against 2026-Q1 · 13F2nd of 6+4.6 pp6 ranked
Dividends
Shareholder yield (Higher is better)————————7.4%FY2025 · SEConly one with it87th81st————————————————————7.4%—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = IRulya Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cabaletta Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Atea Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Kyverna Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; PureTech Health plc: How market caps are worked out; EyePoint Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Zura Bio Ltd: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Relmada Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
IRulya Therapeutics Inc.———
Cabaletta Bio, Inc.———
Atea Pharmaceuticals, Inc.———
Kyverna Therapeutics, Inc.———
PureTech Health plc———
EyePoint Pharmaceuticals, Inc.-776.0%FY2025
2nd percentile in Healthcaremedian -7.7%, 674 companies
1st percentile in USAmedian 3.5%, 2,594 companies
Zura Bio Ltd———
Relmada Therapeutics, Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$88 M$176 M$264 M$351 M20112013201520172019202120232025Atea Pharmaceuticals, Inc. $351 MPureTech Health plc $5 MEyePoint Pharmaceuticals, Inc. $31 MRelmada Therapeutics, Inc. $0 M

Rank in the group

1st2nd2012201320202021202320242025Atea Pharmaceuticals, Inc.: 1st of 2 in 2020Atea Pharmaceuticals, Inc.: 1st of 2 in 2021Atea Pharmaceuticals, Inc.PureTech Health plc: 2nd of 2 in 2023PureTech Health plc: 2nd of 2 in 2024PureTech Health plc: 2nd of 2 in 2025PureTech Health plcEyePoint Pharmaceuticals, Inc.: 1st of 2 in 2012EyePoint Pharmaceuticals, Inc.: 1st of 2 in 2013EyePoint Pharmaceuticals, Inc.: 2nd of 2 in 2020EyePoint Pharmaceuticals, Inc.: 2nd of 2 in 2021EyePoint Pharmaceuticals, Inc.: 1st of 2 in 2023EyePoint Pharmaceuticals, Inc.: 1st of 2 in 2024EyePoint Pharmaceuticals, Inc.: 1st of 2 in 2025EyePoint Pharmaceuticals, Relmada Therapeutics, Inc.: 2nd of 2 in 2012Relmada Therapeutics, Inc.: 2nd of 2 in 2013Relmada Therapeutics, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearIRulya Therapeutics Inc.Cabaletta Bio, Inc.Atea Pharmaceuticals, Inc.Kyverna Therapeutics, Inc.PureTech Health plcEyePoint Pharmaceuticals, Inc.Zura Bio LtdRelmada Therapeutics, Inc.
2025————$5 MESEF2nd$31 MSEC1st——
2024————$5 MESEF2nd$43 MSEC1st——
2023————$3 MESEF2nd$46 MSEC1st——
2022—————$41 MSEC——
2021——$351 MSEC1st——$37 MSEC2nd——
2020——$49 MSEC1st——$34 MSEC2nd——
2019—————$20 MSEC——
2018—————$5 MSEC——
2017—————$8 MSEC——
2016—————$2 MSEC——
2015—————$27 MSEC——
2014—————$3 MSEC——

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of IRulya Therapeutics Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Cabaletta Bio, Inc.CABA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $343 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $343 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Atea Pharmaceuticals, Inc.AVIR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $343 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $343 M (Oct 29, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Kyverna Therapeutics, Inc.KYTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $341 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $341 M (Oct 26, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • PureTech Health plcPRTC · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $350 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $350 M (Aug 1, 2026) · revenue $5 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • EyePoint Pharmaceuticals, Inc.EYPT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $349 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $349 M (Oct 14, 2026) · revenue $31 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Zura Bio LtdZURA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $340 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $340 M (Oct 23, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Relmada Therapeutics, Inc.RLMD · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $337 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $337 M (Oct 20, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Enanta Pharmaceuticals, Inc.ENTA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $334 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $334 M (Oct 16, 2026) · revenue $65 M (year to September 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • X4 Pharmaceuticals, Inc.XFOR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $332 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $332 M (Oct 28, 2026) · revenue $35 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Scribe Therapeutics Inc.SCTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $330 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $330 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Galectin Therapeutics Inc.GALT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $357 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $357 M (Oct 29, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Capricor Therapeutics, Inc.CAPR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $356 M market cap against $343 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $356 M (Oct 23, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.